HKSTP Crowns Overall Champion Skyland Innovation at EPiC 2023 Pitching Competition Beating Over 610 Global Startups
28.4.2023 18:11:00 EEST | Business Wire | Press release
Hong Kong Science and Technology Parks Corporation (HKSTP) today successfully held its 7th Elevator Pitch Competition (EPiC), naming Hong Kong startup, Skyland Innovation, as the overall 2023 champion, beating over 610 startups from 55 economies around the world. The signature event has partnered with the city’s leading corporations: Cathay, HSBC, MTR Lab, plus global accelerator Plug & Play, to become a true iconic mega event that has hit a global scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230428005353/en/
Mr Albert Wong, CEO of HKSTP (Centre), alongside EPiC 2023 Top 10 overall finalists. (Photo: Business Wire)
As Hong Kong’s flagship and largest pitching contest, 50 Grand Finale semi-finalists joined the city’s most eagerly anticipated pitch event this year at sky100 at the top of the International Commerce Centre in West Kowloon to re-create a real-life 60-second elevator pitch experience.
The EPiC 2023 judging panel of the region’s top entrepreneurs, investors and innovation ecosystem leaders selected Skyland Innovation from Hong Kong, as this year’s overall champion. The winner of the grand prize of US$ 90,000, helps property owners and contractors to coordinate and communicate seamlessly on construction sites through the use of robotics and AI. The local proptech is also a spinoff from the Hong Kong Center for Construction Robotics (HKCRC) within the HKSAR Government backed AIR@InnoHK research cluster located at Hong Kong Science Park.
Along with all 50 semi-finalists, Skyland Innovation also qualifies to be considered by the HKSTP Venture Fund for additional investment deals. If selected, each company can potentially receive up to a maximum investment of US$5 million.
EPiC 2023 competitors were split across the two themes of FinTech and PropTech with FinCrime Dynamics from the UK named as the overall FinTech category winner, and Skyland Innovation Company Ltd named the overall PropTech winner from Hong Kong. This year, Canvasland, a FinTech startup from Hong Kong was also voted by the public as the “My Favourite Pitcher" winner, taking away US$10,000 and 200,000 Asia Miles. The top 10 overall finalists also won US$10,000 each (Full winners and finalists list below).
Paul Chan, Financial Secretary of Hong Kong SAR, said: “Hong Kong has a strong, thriving startup ecosystem with 4000 startups, up more than 50% from 2018. Hong Kong is also a natural gateway to the GBA, which offers tremendous growth opportunities. Successful products and services will surely have an edge in the GBA, the whole of the nation and around the world. I am truly excited to be here at EPiC 2023 where startups strive to make their 60-second pitch truly count. I congratulate all the EPiC 2023 winners and invite startups from all over the world to join us in Hong Kong where the future is built.”
Sunny Chai, Chairman, HKSTP, said: “EPiC 2023 showcases the most exciting innovations from the world’s star-studded next-generation global tech ventures. Together with the Hong Kong Government's solid commitment, as reinforced by the Hong Kong I&T Development Blueprint, our city provides the ideal platform to expand into the vast Asian market. Hong Kong is also Asia’s world city and a bridge between the mainland and the world, making us a magnet for global innovation talent and enterprises.”
Albert Wong, CEO, HKSTP, said: “This year’s EPiC competition features a record international turnout and shows Hong Kong is truly back with a strong show of unicorns and soonicorns from around the world among this year’s finalists. But EPiC is more than just a competition, it is a prime example of Hong Kong’s unique ability to help startups grow fast and go beyond by providing a network of global investment opportunities and innovation talent to turn cutting-edge science, technologies, and ideas into game-changing solutions."
A magnet for global investors and innovation talent
EPiC 2023 surpassed all expectations, attracting over 610 entries from 55 countries and cities across five continents. Over 75% of contestants come from overseas, a record high proportion of overseas contestants and economies participation since 2016. Startups joining EPiC 2023 can fully leverage the largest I&T ecosystem in Hong Kong and HKSTP’s direct connections to over 1,000 investors and more than 300 corporate partners.
In addition to the EPiC final pitching contest, the 50 semi-finalists have also taken part in the "Grow Beyond Hong Kong" Immersion Programme. This exclusive 2-day programme ran from 25-26 April, immersed the EPiC 2023 semi-finalists directly into HKSTP’s innovation ecosystem. Participants will unlock growth opportunities through educational talks, business matching and networking with leading corporate partners and investors in our ecosystem.
Winners List:
|
Overall Champion |
Skyland Innovation Company Ltd. |
||
|
“My Favourite Pitcher” Winner |
Canvasland Limited |
||
|
FinTech Winner |
FinCrime Dynamics |
||
|
PropTech Winner |
Skyland Innovation Company Ltd. |
||
|
Top 10 Overall Finalists |
FinTech Finalists:
FinCrime Dynamics Homebase Ultipa VoiceAI Technologies
PropTech Finalists:
I2Cool Limited
Mimicrete VoltSafe, Inc. Skyland Innovation Company Ltd. |
Contestants Breakdown:
|
Category |
|
|
No. of applicants |
|
PropTech |
|
|
266 (43%) |
|
FinTech |
|
|
352 (57%) |
|
|
|
|
|
|
|
|
|
No. of applicants |
|
Overseas |
|
|
465 (75%) |
|
Hong Kong |
|
|
153 (25%) |
A record high proportion of overseas contestants and economies participation since 2016.
For more information on EPiC 2023, please visit: https://epic.hkstp.org/
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that is home to two unicorns and Hong Kong’s leading R&D hub with over 13,000 research professionals and over 1,300 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.
Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimagined for a new generation of industry.
Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong’s international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.
More information about HKSTP is available at www.hkstp.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230428005353/en/
Contact information
Media Contact:
Hong Kong Science and Technology Parks Corporation
Betsy Leung
Tel: +852 2629 2300
Email: betsy.leung@hkstp.org
Edelman Public Relations
Lisa Tse
Tel: +852 3756 8632 / 6347 2009
Email: Lisa.Tse@edelman.com / Edelmanhkstppr@edelman.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom